DiagnoCure, Inc. (CUR.TO), which develops and commercializes high value cancer diagnostic tests, reported a net loss for the fourth quarter of $446,085 or $0.00 per share, compared to a net loss of $1.14 million or $0.03 per share for the year-ago quarter.
Loss from continuing operations for the fourth quarter was $715,749 or $0.01 per share, compared to a loss from continuing operations of $560,186 or $0.01 per share in the prior year quarter.
Total revenues for the fourth quarter increased to $358,996 from $307,475 a year earlier.
by RTT Staff Writer
For comments and feedback: email@example.com